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factorAbstract Corneal neo-vascularisation (NV) is a major sight-threatening condition and is caused by
infections, degenerative disorders, inﬂammation and long-time contact lens wear. Corneal NV
occurs when the balance between angiogenic and antiangiogenic factors is tipped towards angio-
genic molecules. The abnormal vessels may decrease corneal clarity and vision, lead to inﬂammation
and corneal scarring and worsen the prognosis of penetrating keratoplasty if needed.
There is no deﬁnite therapeutic approach for cornea NV. Medical and surgical therapies used to
reduce corneal NV include corticosteroids and non-steroidal anti-inﬂammatory agents, laser photo-
coagulation and needle diathermy. Many of these therapies not only have demonstrated limited suc-
cess but also have associated adverse effects. Therefore, it is very necessary to provide novel
therapeutic approaches. Recently, anti-vascular endothelial growth factor (anti-VGEF) therapy
has been introduced for the management of corneal NV.
Herein, we hypothesise the use of silicate nanoparticles (SiNPs) as a novel treatment for corneal
NV. The penetration rate of SiNPs into the cornea is attributed to the size of nanoparticles. There-
fore, different sizes of SiNPs (20–50 nm) would be prepared and loaded onto the tissue to determine
corneal permeability towards them. In addition, SiNPs would be administered into the eye by top-
ical, subconjunctival and corneal intrastromal injection and accumulate in newly formed vessels.
This hypothesis has been developed by emphasising on the synthesis of SiNPs, characterisation
of size-dependent properties and surface modiﬁcation for the preparation of homogeneousMedical
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tion, shape and/or size of SiNPs could be key factors exerting their antiangiogenic effects, we sug-
gest using 20–30-nm SiNPs to enhance their ability to penetrate into the corneal epithelium. We
hypothesise that topical, subconjunctival and corneal intrastromal injections of SiNPs may effec-
tively inhibit and treat corneal NV. Controlled experimental studies on rabbits are needed to test
whether SiNPs are able to effectively inhibit VEGF-induced angiogenesis in every segment of the
eye including anterior, middle (ciliary body and trabecular mesh work) and posterior segments.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
Nanotechnology has entered the ﬁeld of medicine in recent dec-
ades and is used in different medical ﬁelds including diagnosis,
biosensors and drug delivery and has thus provided novel nan-
omedicines and nanodevices [1]. Researchers are exploring
nanotechnology as a drug delivery route for both systemic med-
ications and ocular applications. Most of the conditions that af-
fect the eye are treatable through the ocular surface [2–4].
Intravitreal administration of pharmacological agents has been
applied for vitreoretinal diseases as drug delivery into the retina
or the vitreous body is difﬁcult to achieve through conventional
methods in the presence of the blood–aqueous barrier and the
inner and outer blood–retinal barriers [5]. For maximising the
drug effect, themolecules of the drug need to reach speciﬁc loca-
tions within the target tissue. Because drug molecules typically
cannot reach their site of action, there is a need for a technology
that can efﬁciently deliver the required amount of the drug to its
target site. Thus, many research studies on nano-sized drug car-
riers have been conducted in the ﬁeld of ophthalmology [6,7].
Nanomedicine uses nanoscale technology for the treatment
and prevention of disease that can pave the way for novel oph-
thalmologic therapeutic applications with an ultimate goal of
improving quality of vision and ﬁnally the quality of life.
Although new drugs have recently been developed within the
ﬁeld of ophthalmology, drugs administered systemically have
poor access to the inside of the eye because of the cornea, which
is an effective barrier to drug penetration by completely sur-
rounding and effectively sealing the superﬁcial epithelial cells.
Conventional systems, such as eye drops, are inefﬁcient, whereas
systemic administration requires high doses resulting in signiﬁ-
cant toxicity. There is a need to develop novel drug delivery car-
riers capable of increasing ocular bioavailability and decreasing
both local and systemic cytotoxicities. Nanotechnology is ex-
pected to revolutionise ocular drug delivery. Many nano-struc-
tured systems have been employed for ocular drug delivery and
yielded some promising results.
The human cornea is normally an avascular, transparent
connective tissue that consists of three layers, epithelium,
stroma and endothelium, and a mechanical barrier to inhibit
transport of exogenous substances into the eye [8]. Each layer
possesses a different polarity and a rate-limiting structure for
drug permeation. The corneal epithelium is of a lipophilic
nature, and tight junctions among cells are formed to restrict
paracellular drug permeation from the tear ﬁlm. The corneal
epithelium is almost impermeable to any substance larger
than 500 Da [9]. Most of the commonly used topical drugs
are larger than that and are not able to cross the cornea. In-
stead, they permeate throughout the conjunctiva and the
underlying sclera, known as ‘non-productive passage’. In-
deed, <5% of topically administered drugs reach intra-ocu-lar tissues [10]. The stroma is composed of an extracellular
matrix of a lamellar arrangement of collagen ﬁbrils. Drugs
administered systemically because of the blood–aqueous and
blood–retinal barriers and annular tight junctions, which
make the cornea a major ocular barrier, have poor access
to the retina and corneal stroma. Nanoparticle (NP)-
mediated delivery not only overcomes the corneal epithelial
barrier but can also prolong the resistance time of a drug
in the pre-corneal tear-ﬁlm layer. Therefore, preparing a top-
ical nano-drug which is able to pass through ocular barriers
is desirable [11].
New vessels, which sprout from the capillaries and venules
of the pericorneal plexus, may block light, compromise visual
acuity, worsen the prognosis of penetrating keratoplasty and
lead to inﬂammation, corneal scarring and oedema [12]. In
the clinical setting, topical corticosteroids and non-steroidal
anti-inﬂammatory drugs (NSAIDs) remain the principal pri-
mary treatment for corneal vessels [13]. However, in corneas
in which vessels have been established, corticosteroid and
NSAID treatments are ineffective. Although laser photocoag-
ulation for corneal NV has been reported [14,15], this method
achieves an inadequate effect because of the high incidence of
recanalisation and thermal damage to adjacent tissue [16].
Other treatments including photodynamic therapy, ﬁne needle
diathermy and conjunctival, limbal and amniotic membrane
transplantation [17–19] have limited clinical efﬁcacy and also
cause a multitude of undesirable side effects. Therapeutic NP
technologies have the potential for parenteral, oral, ocular
and trans-dermal applications as well as used in sustained re-
lease formulations and as a carrier for radionucleotides in nu-
clear medicine [20]. Sustained drug delivery systems can
provide sustained drug levels to a particular tissue, thereby sig-
niﬁcantly reducing the dosing frequency and the associated
complications. Several delivery systems including implants,
scleral plugs and microparticles and NPs have been used for
this purpose [21–23]. The particulate systems offer several
advantages including ease of repeated injections and cellular
entry [24]. NPs of various molecules, such as gold and silver,
have been reported to have an antiangiogenic effect on patho-
logical NV [25–27]. Silicate NPs (SiNPs) have been used in
drug delivery, gene therapy, biolabelling and in combination
with other treatment modalities [28–30]. Some characters of
nano-sized silica which are size, size distribution and morphol-
ogy are of great importance to its application. The large size is
usually not effective for biomedical applications as cell uptake
is limited. Another important requirement in the biomedical
application of SiNPs is their aqueous suspensibility. Often,
the high-temperature removal of the template poses problems
in suspension in solution or destruction of encapsulated agents
[31–33]. Many technologies have been explored to fabricate
nanostructures and nanomaterials. In most of the preparation
16 M. Mohammadpour et al.methods, it is very difﬁcult to control the size and shape of the
particle except for the micro-emulsion method, in which we
need to control one factor and that will control everything
else for particle synthesis. A micro-emulsion is a thermody-
namically stable dispersion of two immiscible ﬂuids; the
system is stabilised by added surfactant. In reverse
micro-emulsion, the surfactant molecule dissolved in organic
solvents forms spherical micelles. In the presence of water,
the polar head groups organise themselves to form
micro-cavities containing water, which are often called re-
verse micelles [34]. Besides effective control of the particle
characteristics, simple operation and apparatus, mild reac-
tion conditions which do not need high temperature and
pressure are all inclusive [35,36]. One signiﬁcant challenge
for the successful development of therapeutic NPs is rapid
clearance during systemic delivery [37]. Therefore, the factors
that could affect the clearance and biodistribution of NPs,
such as particle physicochemical properties and targeting
legends [38], should be carefully considered for the optimal
design of therapeutic NPs [39]. The fact that no direct
toxicity of SiNPs was observed on retinal neuronal or endo-
thelial cells, nor on the retinal tissue [40]. prompted us to
hypothesise that topical, subconjunctival and corneal intra-
stromal injections of SiNPs would effectively inhibit corneal
NV with minimal side effects.
Hypothesis
According to the above-mentioned evidence and the antian-
giogenic effects of SiNPs and the fact that SiNPs have no
toxic effect on retinal tissue [40], it seems to be reasonable
that topical, subconjunctival and corneal intrastromal injec-
tions of SiNPs can be a novel treatment for corneal NV
with minimal side effects. As the importance of concentra-
tion, shape and size of SiNPs could be key factors exerting
their antiangiogenic effects, we suggest using 20–30-nm SiN-
Ps to enhance their ability to pass through the corneal tight
junctions and reach the new vessels in the corneal stroma.
Further studies can be performed on the efﬁcacy of SiNPs
on other ocular segments to control neo-vascular glaucoma
and retinal NV due to diabetic retinopathy and vascular
occlusive disorders (Figs. 1 and 2).Figure 1 Structure of corneal epithelial tight junctionsHow to synthesise SiNPs
Generally, it is possible to produce particles in the nanometre
size range by nucleation of NPs from supersaturated solution.
Here, a two-phase nucleation method [42] has been suggested
as a simple synthesis route for producing ultra-monodisperse
SiNPs between 5 and 50 nm. This method is based on the very
slow increase of the solution supersaturation and on the use of
peptides for the silica condensation catalysis. Therefore, using
tetraethylorthosilicate (TEOS) as an organic layer above the
aqueous solution could limit the increase rate of silica mono-
mer in the aqueous solution by controlling the TEOS hydroly-
sis rate. Dilution of TEOS in an inert oil further limits TEOS
hydrolysis and allows the control of the water solution super-
saturation increase rate. Indeed, existence of the interfacial
area between the organic layer containing the TEOS molecules
and the water phase is responsible for physical limits of TEOS
hydrolysis.
In brief, different amounts of L-arginine as a catalyst are
dissolved in 40 ml of water. Then, a certain volume of cyclo-
hezane is added. To keep an aqueous phase undisturbed,
TEOS is add subsequently [40]. The two-phase solution is left
to warm for several minutes under agitation. The stirring rate
is ﬁxed such that the top organic layer is left almost undis-
turbed and the water phase is well mixed. By this method,
we will be able to prepare spherical silica particles (5–50 nm)
by controlling reaction factors. The size of silica displayed
decreasing variation with the increase of L-arginine and de-
crease of temperature. The mean particle size could be deter-
mined by dynamic light scattering (DLS), Fig. 3.
The morphology of the NPs would be investigated by scan-
ning electron micrography (SEM), Fig. 4, and transmission
electron microscopy (TEM) [43].Investigation of penetration of SiNPs into cornea
We should use in vitro permeability studies to determine
whether NPs can penetrate into the cornea to gain access to
the deep stroma and whether NPs can cross the cornea to gain
access to the vitreous area.and possible way of SiNPs to penetrate this barrier.
Figure 2 Ligands for different VEGF receptors. SiNP molecule can not only block the VEGF1 receptors but also can effectively inhibit
VEGF 2 and VEGF 3 receptors, simultaneously.
Figure 3 Scattered intensity of the nanoparticles in the aqueous
phase after 16 h of reaction times in a two-phase reactor at 60 C
and different R and L-Arginine concentration by Dynamic Light
Scattering DLS.
Figure 4 The SEM image of spherical silica nanoparticle.
[L-Arginine] = 6 mM/L, reaction time: 24 h, T= 26±1 C, at
low agitation rate.
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tissue, SEM was used. After performing the transport across
the tissues as described above, the part of the tissue exposed
to the NP suspension was cut off from the rest of the tissue
and embedded in an optimal cutting temperature (OCT) med-
ium for frozen sectioning. The eyes were kept at 80 C before
sectioning. Sections around 10 lm in thickness were cut and
visualised using SEM.
Evaluation of hypothesis
An animal (rabbit) model experimental study is suggested
to test this novel hypothesis. A study with two arms is sug-gested. One group would receive topical, subconjunctival
and corneal intrastromal injections of SiNPs before corneal
NV, which is induced by vascular endothelial growth factor
(VEGF) to evaluate inhibition of SiNPs towards cornea
NV. The other group would receive topical, subconjuncti-
val, and corneal intrastromal injections of SiNPs after cor-
neal NV to evaluate treatment of SiNPs towards corneal
NV. In addition, the level of NV in the corneas of all rab-
bits would be monitored and quantiﬁed with a micrometer-
calibrated stereomicroscope equipped with a digital
camera.
Discussion
Corneal NV occurs as a result of disequilibrium between
angiogenic and antiangiogenic stimuli. Angiogenesis is the pro-
cess of new blood vessel growth from pre-existing vascular
18 M. Mohammadpour et al.structures. Corneal angiogenesis occurs in several pathological
conditions and brings about a variety of unwanted conse-
quences. Corneal angiogenic factors include VEGF. This
factor promotes vascular endothelial cell proliferation,
migration and tube formation [41]. It also increases vascular
leakage and promotes monocyte chemotaxis and b-cell pro-
duction in mice, indicating the key role of VEGF in inﬂam-
mation [42]. VEGF binds to two members of a receptor
tyrosine kinase family, VEGF receptor (VEGFR)-1 and
VEGFR-2, also known as Flt-1 and kinase insert domain
receptor (KDR), respectively. VEGFR-2 is considered the
main VEGF receptor and mediates the proliferative effects
of VEGF on vascular endothelial cells. VEGF binding to
VEGFR-2 induces the dimerisation and subsequent auto-
phosphorylation of receptors by intracellular kinase do-
mains, which leads to a mitogenic and proliferative signal
[43]. VEGF and VEGF-dependent signalling pathways are
known to be involved in pathological NV. In particular,
VEGFR-2 is considered to play a pivotal role in develop-
mental angiogenesis [44]. This theory assumes that SiNPs
effectively suppressed phosphorylation of VEGFR-2. This
result suggested that the mechanism of antiangiogenic effects
of SiNPs was also based on inhibition of VEGFR-2 activa-
tion. Among downstream pathways of VEGFR-2 signalling,
protein kinase C/MARK (protein kinase C–MAP/microtu-
bule afﬁnity-regulating kinase) and phosphoinositide 3-ki-
nase/AKT (PI3K/AKT) pathways are known to be
involved in processes of angiogenesis [45,46].
The requirement of VEGF for corneal NV was ﬁrst
demonstrated in a rat model where NV was later subse-
quently blocked by anti-VEGF antibodies [47,48]. Indeed,
anti-VEGF antibodies have shown initial therapeutic suc-
cess. Bevacizumab is a humanised murine monoclonal anti-
body that recognises all isoforms of VEGF. Bevacizumab
was initially approved to treat metastatic colon cancer
[49] but has also shown efﬁcacy in partial reduction of cor-
neal NV through topical, subconjunctival and intra-ocular
applications of bevacizumab [50–53]. NPs of antibiotics
have also been suggested for treatment of ocular infections.
The initial antibiotic regimens should be changed from time
to time to prevent multidrug resistance. Therefore, resis-
tance to antibiotics such as chloramphenicol, cefazolin
and trimethoprim towards Pseudomonas aeruginosa (PA),
which is the leading cause of contact lens-induced keratitis
and corneal ulcers, is very common and these antibiotics
should not be considered. Previously, we reported that
PA was highly sensitive to ceftazidime, ciproﬂoxacin and
amikacin [54]. The authentic value of an anti-Pseudomonas
NP such as ceftazidime in decreasing PA keratitis/endoph-
thalmitis morbidities can be evaluated in well-designed
experimental animal models [55].
The bioavailability of an instilled conventional drug onto
the ocular surface is usually low. Most of it is lost due to phys-
iological mechanisms, such as tear drainage and blinking, a
few seconds after instillation [56]. Therefore, there is limited
absorption of the drug and limited access to intra-ocular tis-
sues through the conjunctival–scleral pathway [57]. Indeed,
NPs were considered to offer the possibility of more facile
delivery and transport across tissues.
The intrinsic capacity of NPs to adhere to the ocular sur-
face and interact with the epithelium has stimulated
researchers to ﬁnd applications for them in ophthalmology.The possibility of the controlled release of drugs that sur-
pass the ocular barriers and effectively reach the target is
the ability that makes them applicable to treat eye diseases.
Nanoparticulate systems improve the delivery of poorly
water-soluble drugs while signiﬁcantly reducing toxicity com-
pared to the free drug [58]. There are several different
modalities for ocular drug administration. The most com-
mon include liquids topically applied onto the front of the
eye in the form of eye drops, subconjunctival or sub-Tenon’s
injection in the conjunctival tissue or below the Tenon’s cap-
sule and intravitreal injection.
Dong and his co-workers demonstrated that SiNPs had
negligible acute toxicity to retinal neuronal cells, retinal endo-
thelial cells and the retinal tissue at concentrations 100 times
the effective therapeutic dosage. In addition, they reported that
SiNPs had antiangiogenic effects [40].
We want to note that reports of other groups suggested
the antiangiogenic effects of 50 nm gold (AuNPs) and silver
NPs [39,27]. These results suggest that the concentration,
shape or size of NPs could be key factors exerting their anti-
angiogenic effects. According to tight junctions between cor-
neal epithelial cells, the small size of NPs (20–50 nm) will be
effective for increasing drug penetration into deep corneal
stromal layers that warrants NP efﬁcacy. The physicochem-
ical characteristics of SiNPs are critical for cellular uptake,
intracellular trafﬁcking and interaction with plasma proteins.
Nonetheless, the issue of biodistribution of NPs should be
addressed in their biomedical application. Therefore, biodeg-
radation and biodistribution of NPs might be investigated
before their clinical application.
We believe that SiNPs as well as AuNPs are able to in-
hibit the phosphorylation of extracellular signal-regulated ki-
nases 1 and 2 (ERK 1/2), a signalling molecule on the
MARK pathway, not that of AKT. Furthermore, mass-pro-
duced SiNPs may be more feasible and cost-effective than
monoclonal antibodies such as avastin or bevacizumab. In
addition, SiNPs could have modiﬁable size and concentra-
tion. Using topical, subconjunctival and corneal intrastromal
injections of SiNPs as an anti-VEGF therapy seems effective
in suppressing new vessel formation and vascular leakage,
which can improve visual function.
In conclusion, we suggest that SiNPs, because of their small
size, can have acceptable permeability through the corneal epi-
thelial tight junctions and can be safely considered an effective
modality in the prevention and treatment of corneal NV. Fur-
ther studies can be performed on the efﬁcacy of SiNPs on
other ocular segments to control neo-vascular glaucoma and
retinal NV due to diabetic retinopathy and vascular occlusive
disorders.Conﬂict of interest statement
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subject?
Corneal NV is a serious condition that can lead to a
profound decline in vision. The abnormal vessels block
light, compromise visual acuity, cause corneal scarring
and may lead to oedema.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
This theory assumes that topical, subconjunctival and
corneal intrastromal injection of SiNPs is a novel ther-
apeutic approach for the treatment of cornea NV,
which is more feasible and cost-effective than mono-
clonal antibodies such as avastin. Further, SiNPs
could have modiﬁable size and concentration. There
is no adverse reported side effect in intravitreal injec-
tion of SiNPs. Therefore, it is reasonable to hypothe-
sise that subconjunctival and corneal intrastromal
injections of SiNPs would not have any direct toxicity.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
Preliminary experimental studies on animal models
where corneal NV is induced by VEGF are suggested.References
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